[68Ga]DOTA-FD3

Radionuclide: Ga-68 t½ 67.71 min
Modality: PET
Production route: —
Stage: Preclinical
Syntheses indexed: 1

Preclinical only, no clinical indication yet

What it is

Compound class: FAP-targeted peptide, DOTA-conjugated
Target / mechanism: Fibroblast activation protein (FAP) PMID 38706713
Clinical application: FAP-overexpressing tumors, including pancreatic cancer with abundant stroma; imaging of primary and metastatic tumors PMID 38706713
Theranostic pair: [177Lu]Lu-DOTA-FD3

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	none	—	94%	FD3	38706713 2023 Research (Wash D C) This mixture was added to 400 μl of 68GaCl3 solution (containing 37 MBq) in 0.1 M HCl, with pH adjusted to 4.0 using 0.1 M NH4OAC. The mixture was incubated at 100 °C for 10 min without any additional purification steps.

Need this precursor?We can point you to suppliers for [68Ga]DOTA-FD3, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 38706713. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. | Stage 30 (2026-09-18): Modality was 'Therapy' -- a bucket value given to every agent found by the therapy-oriented bulk search (stages 21-22), not a source statement. Corrected to PET: Ga-68 is a positron emitter used only for PET imaging. Linked articles: PMID 38706713. Compound class inferred from precursor name (not stated outright) -- PMID 38706713: 'approximately 20 nmol of FD1, FD2, or FD3 was dissolved in 20 μl of dimethyl sulfoxide'. Stage set/updated at stage 39 from PMID 38706713: 'The diagnostic and therapeutic potential of the agents labeled with 68Ga and 177Lu was assessed in several tumor models exhibiting different levels of FAP expression.'.